Evaluating the Inflammasome Multi-Protein Complex for Therapeutic Targeting, Connecting Proof-of-Concept Biomarkers & Disease Endpoints & Assessing Combination Therapy to Achieve Clinical Efficacy
Now in its 7th year, the Inflammasome Therapeutics Summit is the only industry forum focused exclusively on inflammasome-targeted drug development. Join 70+ experts from discovery to clinic, including leading drug developers, translational scientists, and clinical strategists to:
- Share insights and benchmark progress across neuroinflammation, metabolic, and autoimmune indications
- Dive into the latest clinical data, emerging mechanisms, and translational breakthroughs
- Connect with those driving the field forward and shape the next wave of innovation
Join your peers to hear directly from those driving programs forward, tackle the most pressing translational challenges, and help chart the future of inflammasome therapeutics.
What stood out was the presence of new players in the space who showcased their early-stage programs, offering fresh perspectives.
Great to get insights from other biopharma companies with ongoing clinical trials as well as academics that had high-quality talks.
Cutting-edge updates on where this field stands, with notable highlights on the CNS area and discussions around NLRP3 applications.
Explore the 2025 Full Event Guide
- 20+ Inflammasome Expert Speakers
- 10+ C-Suites & Vice Presidents
- 5+ Pivotal Clinical Readouts
- 3 Interactive Workshops
- 8+ Hours of Networking
2025 Expert Speakers Included:
2025 Partners
Explore the Agenda
Discover the key discussions from the summit, covering breakthroughs in inflammasome biology, emerging therapeutic targets, and the latest clinical and translational insights.
Partner With Us
Showcase your expertise alongside organizations advancing inflammasome-targeted drug development, from biomarker discovery to translational and clinical research.
Join Biopharma Experts
Connect with leading drug developers, immunology researchers, and biotech innovators working to advance the next generation of inflammasome therapeutics.